What It Is
Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two complementary hormonal pathways for comprehensive metabolic effects. This next-generation metabolic peptide coordinates glucose control and appetite regulation through dual receptor activation.
How It Works
Tirzepatide activates both GIP and GLP-1 receptors, creating synergistic effects: GLP-1 signalling reduces appetite and improves glucose control, while GIP signalling enhances insulin secretion and increases energy expenditure. Together, they provide comprehensive metabolic support exceeding single-agonist approaches.
Key Benefits & Use Cases
- Potent appetite suppression and satiety
- Enhanced glucose control and insulin sensitivity
- Increased metabolic rate and energy expenditure
- Comprehensive body composition support
General Dosage Information
Research protocols typically use 2.5-15mg injected subcutaneously once weekly. Dosing escalates gradually from lower starting doses. The long half-life supports once-weekly administration.